<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487704</url>
  </required_header>
  <id_info>
    <org_study_id>XJYFY-KRLZ-HCC-1</org_study_id>
    <nct_id>NCT04487704</nct_id>
  </id_info>
  <brief_title>Carrillizumab is Used for Advanced Liver Cancer</brief_title>
  <official_title>A Real World Study of Treatment Regimens Containing Camrelizumab in Patients With Advanced Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      camrelizumab ， a humanized monoclonal antibody against PD-1, has been shown to block the
      binding of PD-1 to PD-L1, thereby inhibiting the immune escape of tumor cells. It has a high
      affinity for PD-1 (KD = 3.31 nmol/L), a high acceptor proportion (85% at 200 mg) of
      circulating T lymphocytes, and binds to epitopes different from Nivolumab and
      pembrolizumab，Phase 1 clinical trials have shown that camrelizumab is well tolerated and has
      antitumor activity in patients with advanced solid tumors.camrelizumab has been approved for
      indication for advanced hepatocellular carcinoma The main objective of this study was to
      observe and evaluate the safety and efficacy of treatment regiments containing carrelizumab
      in advanced liver cancer。 The subjects included people over 18 years old， For men and women
      with advanced liver cancer confirmed by histopathology or cytology;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Safety as defined by the NCI CTCAE v5.0</measure>
    <time_frame>From ptients participate in the clinical study to 90 days after the end of treatment</time_frame>
    <description>Adverse evets as graded by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>1-year, 3-year, 5-year survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab in the treatment of liver cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Camrelizumab intravenous infusion (no need for prophylactic administration), no less than 30 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>camrelizumab</intervention_name>
    <description>camrelizumab 200 mg, intravenous infusion (no need for prophylactic administration), no less than 30 min ，No more than 60 min, Q2W, one cycle every 2 weeks (14 days) or Q3W, one cycle every 3 weeks (21 days). Try to complete the administration before the ECG</description>
    <arm_group_label>Camrelizumab in the treatment of liver cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or more;

          -  For both men and women;

          -  Patients with advanced liver cancer confirmed by histopathology or cytology;
             .Volunteer to join the study, sign the informed consent, good compliance, and
             cooperate with the follow-up.

        Exclusion Criteria:

          -  A known allergy to the study drug or any of its excipients; Or had a severe allergic
             reaction to other monoclonal antibodies;

          -  Patients who are ready for or have previously received an organ or allogeneic bone
             marrow transplant;

          -  Pregnant or lactating women;

          -  According to the judgment of the researcher, the patients should not be included in
             this study。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Lyu, MD,phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Lyu, MD,phD</last_name>
    <phone>86-029-85323900</phone>
    <email>luyi169@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui Qu</last_name>
    <phone>86-18681943306</phone>
    <email>1289271841@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Lv, MD,PHD</last_name>
      <phone>0086-13991200581</phone>
      <email>luyi169@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaogang Zhang, Phd</last_name>
      <phone>0086-13891803523</phone>
      <email>zzsghr@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Lv, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RWS</keyword>
  <keyword>Advanced Liver Cancer</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

